Stock Track | Summit Therapeutics Plummets 5.01% Intraday as H.C. Wainwright Cuts Target Price Amid Clinical Data Concerns

Stock Track

05/08

Summit Therapeutics PLC's stock plummeted 5.01% during intraday trading on Thursday, extending recent weakness in the biotechnology sector.

The decline follows H.C. Wainwright's decision to cut its target price on the company from $30 to $23, compounding ongoing negative sentiment from the HARMONi-3 study's interim progression-free survival analysis in squamous non-small cell lung cancer, which failed to reach statistical significance. Multiple institutions have since lowered their target prices, creating a negative resonance effect in the market.

The company had previously disclosed that the HARMONi-3 interim data failed to meet success criteria, triggering a significant single-day decline in late April. While the stock had briefly rebounded after some analysts maintained positive ratings, H.C. Wainwright's recent downgrade has again weighed on market confidence. Investors are now looking ahead to the final HARMONi-3 PFS results expected in the second half of the year and the upcoming HARMONi-6 overall survival data presentation at ASCO.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1170799787"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170799787\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170799787?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 01:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170799787","market":"us","top_or_hot":-1,"title":"Stock Track | Summit Therapeutics Plummets 5.01% Intraday as H.C. Wainwright Cuts Target Price Amid Clinical Data Concerns","media":"Stock Track","content":"<p>Summit Therapeutics PLC's stock plummeted 5.01% during intraday trading on Thursday, extending recent weakness in the biotechnology sector.</p><p>The decline follows H.C. Wainwright's decision to cut its target price on the company from $30 to $23, compounding ongoing negative sentiment from the HARMONi-3 study's interim progression-free survival analysis in squamous non-small cell lung cancer, which failed to reach statistical significance. Multiple institutions have since lowered their target prices, creating a negative resonance effect in the market.</p><p>The company had previously disclosed that the HARMONi-3 interim data failed to meet success criteria, triggering a significant single-day decline in late April. While the stock had briefly rebounded after some analysts maintained positive ratings, H.C. Wainwright's recent downgrade has again weighed on market confidence. Investors are now looking ahead to the final HARMONi-3 PFS results expected in the second half of the year and the upcoming HARMONi-6 overall survival data presentation at ASCO.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Summit Therapeutics Plummets 5.01% Intraday as H.C. Wainwright Cuts Target Price Amid Clinical Data Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Summit Therapeutics Plummets 5.01% Intraday as H.C. Wainwright Cuts Target Price Amid Clinical Data Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-08 01:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Summit Therapeutics PLC's stock plummeted 5.01% during intraday trading on Thursday, extending recent weakness in the biotechnology sector.</p><p>The decline follows H.C. Wainwright's decision to cut its target price on the company from $30 to $23, compounding ongoing negative sentiment from the HARMONi-3 study's interim progression-free survival analysis in squamous non-small cell lung cancer, which failed to reach statistical significance. Multiple institutions have since lowered their target prices, creating a negative resonance effect in the market.</p><p>The company had previously disclosed that the HARMONi-3 interim data failed to meet success criteria, triggering a significant single-day decline in late April. While the stock had briefly rebounded after some analysts maintained positive ratings, H.C. Wainwright's recent downgrade has again weighed on market confidence. Investors are now looking ahead to the final HARMONi-3 PFS results expected in the second half of the year and the upcoming HARMONi-6 overall survival data presentation at ASCO.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"","article_id":"1170799787","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170799787","pubTimestamp":1778174117,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Summit Therapeutics PLC's stock plummeted 5.01% during intraday trading on Thursday, extending recent weakness in the biotechnology sector.The decline follows H.C. Wainwright's decision to cut its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMMT":"Summit Therapeutics PLC"},"translate_title":"个股追踪|Summit Therapeutics盘中暴跌5.01%因H.C.由于临床数据担忧，温赖特下调目标价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1},"content_text":"Summit Therapeutics PLC's stock plummeted 5.01% during intraday trading on Thursday, extending recent weakness in the biotechnology sector.The decline follows H.C. Wainwright's decision to cut its target price on the company from $30 to $23, compounding ongoing negative sentiment from the HARMONi-3 study's interim progression-free survival analysis in squamous non-small cell lung cancer, which failed to reach statistical significance. Multiple institutions have since lowered their target prices, creating a negative resonance effect in the market.The company had previously disclosed that the HARMONi-3 interim data failed to meet success criteria, triggering a significant single-day decline in late April. While the stock had briefly rebounded after some analysts maintained positive ratings, H.C. Wainwright's recent downgrade has again weighed on market confidence. Investors are now looking ahead to the final HARMONi-3 PFS results expected in the second half of the year and the upcoming HARMONi-6 overall survival data presentation at ASCO.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}